CYP19A1 and breast cancer: And in 2004, the American Society of Clinical Oncology (ASCO) Technology Assessment recommended that, an aromatase inhibitor should be included to reduce the risk of tumor recurrence when treating the hormone-sensitive early-stage breast cancer [13].